More News

08 Aug 2019 Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
06 Aug 2019 Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement
05 Aug 2019 Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence
05 Aug 2019 Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership
01 Aug 2019 ImCheck Therapeutics Awarded €2 Million From Bpifrance to Advance its First-in-class Immunotherapy Program Into the Clinic
01 Aug 2019 Rewind Therapeutics Awarded €2.9 Million VLAIO Grant to Discover and Develop Novel Drug Candidates for Myelin-related Neurological Diseases
01 Aug 2019 Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer
31 Jul 2019 REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector
31 Jul 2019 Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate
29 Jul 2019 Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine
27 Jul 2019 Zambon completes transformational acquisition of Breath Therapeutics
25 Jul 2019 REGENXBIO and Neurimmune Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases
24 Jul 2019 Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
23 Jul 2019 IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program
23 Jul 2019 Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa
23 Jul 2019 DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
21 Jul 2019 Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
18 Jul 2019 Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
18 Jul 2019 Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors
18 Jul 2019 Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
17 Jul 2019 PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema
17 Jul 2019 Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss
17 Jul 2019 Gotham Therapeutics and Mercachem Announce Progress in Compound Library Development Tailored for Epitranscriptomic Drug Discovery
16 Jul 2019 Skyhawk Therapeutics Announces Agreement with Genentech to Discover and Develop Small Molecule RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases
16 Jul 2019 Convelo Therapeutics Enters Into Collaboration and Option to Acquire Agreement With Genentech to Discover Novel Remyelinating Therapies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up